Page 4 - Strides Pharma
Strides Pharma resumes sales of antacid drug Ranitidine in Australia
Strides predominantly sells Ranitidine tablets in the US markets
 "Strides Pharma resumes sales of antacid drug Ranitidine in Australia")
Strides acquires USFDA approved manufacturing facility in Florida
Strides Pharma Science said the site has undergone several successful USFDA inspections and has no outstanding observations
 "Strides acquires USFDA approved manufacturing facility in Florida")
Strides Pharma soars 12% after Co announces JV with Chinese firm
Strides Pharma Global Pte (Singapore) and Sun Moral International (Hong Kong), a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings, have entered into a JV to form called Sihuan Strides.
 "Strides Pharma soars 12% after Co announces JV with Chinese firm")
Strides Pharma announces JV with Chinese firm to launch its products
The development comes in the backdrop of the recent regulatory developments in China which has enabled fast track approvals of differentiated high-quality generics approved in key regulated markets
 "Strides Pharma announces JV with Chinese firm to launch its products")
Strides Bengaluru unit gets 'Voluntary Indicated Action' status from USFDA
The flagship facility in Bengaluru is the largest manufacturing facility for the company with capabilities to produce finished dosage products across multiple formats
 "Strides Bengaluru unit gets 'Voluntary Indicated Action' status from USFDA")
US health regulator wants action against Strides Pharma's Puducherry unit
USFDA has classified the facility as OAI based on the inspection conducted from January 28 to February 5, 2019
 "US health regulator wants action against Strides Pharma's Puducherry unit")
Strides Pharma gains 6% as JV receives approval for Albendazole tablets
The stock moved higher by 6.4% to Rs 458 on BSE after the company announced that its JV has received USFDA nod for tapeworm infection treatment drug.
 "Strides Pharma gains 6% as JV receives approval for Albendazole tablets")
Strides Pharma Q2 net loss at Rs 87 million on poor operating income
Consolidated revenue also saw a marginal degrowth of 4.6 per cent at Rs 7.3 billion
Strides Pharma to get $20 mn funding for consumer healthcare business
The stocks of Strides Pharma Science were trading flat at Rs 426.35 per scrip on the BSE, up 3.05 per cent over its previous close
 "Strides Pharma to get $20 mn funding for consumer healthcare business")
Strides Pharma receives USFDA approval for antiepileptic drug Gabapentin
The product will be marketed by Strides Pharma Inc in the US market
 "Strides Pharma receives USFDA approval for antiepileptic drug Gabapentin")
Strides Pharma gets US FDA approval for hypokalemia treatment drug
The tablets, used to treat hypokalemia, will be available in 600 mg and 750 mg dosage
 "Strides Pharma gets US FDA approval for hypokalemia treatment drug")
